AIMS: Estimation of prevalence of autoimmune thyroid disorders in Greek breast cancer patients (prospective study). METHODS: The prevalence of autoimmune thyroiditis was estimated in 310 Greek breast cancer patients, in 100 women with benign breast disease and in 190 women without any breast disease, by submitting them to clinical examination, ultrasound thyroid evaluation, serum thyroid antibody determination and fine needle aspiration (FNA) of the thyroid gland. RESULTS: Autoimmune thyroiditis was found in 136/310 (43.9%) breast cancer women: 95 were diagnosed by positive autoantibodies, 19 had positive FNA findings and 22 had both positive autoantibodies and positive FNA findings. In 117 cases, thyroid autoantibodies were positive (37.7% whereas the control groups had respective rates of 19% and 18.4% autoantibody positivity). CONCLUSIONS: There is evidence of high incidence of autoimmune thyroiditis in Greek breast cancer patients, increasing in relation to cancer stage. Copyright 2001 Harcourt Publishers Limited.
AIMS: Estimation of prevalence of autoimmune thyroid disorders in Greek breast cancerpatients (prospective study). METHODS: The prevalence of autoimmune thyroiditis was estimated in 310 Greek breast cancerpatients, in 100 women with benign breast disease and in 190 women without any breast disease, by submitting them to clinical examination, ultrasound thyroid evaluation, serum thyroid antibody determination and fine needle aspiration (FNA) of the thyroid gland. RESULTS:Autoimmune thyroiditis was found in 136/310 (43.9%) breast cancerwomen: 95 were diagnosed by positive autoantibodies, 19 had positive FNA findings and 22 had both positive autoantibodies and positive FNA findings. In 117 cases, thyroid autoantibodies were positive (37.7% whereas the control groups had respective rates of 19% and 18.4% autoantibody positivity). CONCLUSIONS: There is evidence of high incidence of autoimmune thyroiditis in Greek breast cancerpatients, increasing in relation to cancer stage. Copyright 2001 Harcourt Publishers Limited.
Authors: C Chiappa; F Rovera; S Rausei; S Del Ferraro; A Fachinetti; M Lavazza; V Marchionini; V Arlant; M L Tanda; E Piantanida; H Y Kim; A Anuwong; G Dionigi Journal: J Endocrinol Invest Date: 2016-09-13 Impact factor: 4.256
Authors: Orhan Turken; Yavuz NarIn; Sezai DemIrbas; M Emin Onde; Ozkan Sayan; E Gokhan KandemIr; Mustafa YaylacI; Ahmet Ozturk Journal: Breast Cancer Res Date: 2003-06-05 Impact factor: 6.466
Authors: Nancy Bueno Figueiredo; Sílvia Helena Cestari; Sandro José Conde; Renata Azevedo Melo Luvizotto; Maria Teresa De Sibio; Denise Perone; Maria Lúcia Hirata Katayama; Dirce Maria Carraro; Helena Paula Brentani; Maria Mitzi Brentani; Célia Regina Nogueira Journal: ScientificWorldJournal Date: 2014-01-23
Authors: T P McVeigh; R J Mulligan; U M McVeigh; P W Owens; N Miller; M Bell; F Sebag; C Guerin; D S Quill; J B Weidhaas; M J Kerin; A J Lowery Journal: Endocr Connect Date: 2017-09-12 Impact factor: 3.335